Latest Press Releases 11.30.22 Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic 11.07.22 Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs 10.24.22 Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic 10.11.22 Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022 10.06.22 Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022 09.22.22 Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660 Download PDF 08.09.22 Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic 05.24.22 Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic 09.29.21 Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties Download PDF 09.22.21 Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021 Download PDF 05.21.21 Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection Download PDF 02.17.21 Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health Download PDF 10.21.20 Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020 Download PDF 05.06.20 Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660 Download PDF 02.04.20 Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660 Download PDF 08.21.19 Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research Download PDF 06.26.19 Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019 Download PDF 06.14.19 Statement: Response to FDA Safety Alert Regarding the Use of Fecal Microbiota for Transplantation Download PDF 05.17.19 Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted Download PDF 03.20.19 MICROBIOME HEALTH INDEX™ Platform to be Presented at Gut Microbiota for Health Summit 2019 Download PDF 11.01.18 Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month Download PDF 10.22.18 Rebiotix MICROBIOME HEALTH INDEX™ Data to be Presented at United European Gastroenterology Annual Conference Download PDF 10.03.18 Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease States Download PDF 10.01.18 Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018 Download PDF 06.08.18 MICROBIOME HEALTH INDEX™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018 Download PDF 06.04.18 Rebiotix Microbiota Restoration Therapy™ Products, MICROBIOME HEALTH INDEX™ to Take Center Stage at Digestive Disease Week 2018 Download PDF 06.01.18 Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention Download PDF 04.24.18 Rebiotix Presents Posters at ECCMID 2018 Highlighting MICROBIOME HEALTH INDEX™ Value Potential and RBX2660 Phase 2 Clinical Program Data Download PDF 04.05.18 Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc. Download PDF 03.27.18 Rebiotix’s Lee Jones to Receive TRUST 2018 Courageous Women in Health Care Award Download PDF 03.12.18 Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe Download PDF 02.12.18 Rebiotix Develops MICROBIOME HEALTH INDEX™ to Identify Indicators for Microbiome Restoration Download PDF 01.09.18 Rebiotix Highlights 2017 Achievements and 2018 Objectives Download PDF 01.05.18 Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy™ Download PDF 01.04.18 Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week Download PDF 11.29.17 Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms Download PDF 11.15.17 Rebiotix to Present at 29th Annual Piper Jaffray Healthcare Conference Download PDF 11.02.17 Rebiotix and the C. diff. Foundation Applaud the State of Minnesota as it Declares November C. Difficile Infection Awareness Month Download PDF 10.16.17 New Clinical Data and Microbiome Research from Rebiotix’s Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017 Download PDF 10.12.17 Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017 Download PDF 10.04.17 Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix RBX2660 Phase 2 Studies Download PDF 09.06.17 Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs Download PDF 08.23.17 Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference Download PDF 08.07.17 Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection Download PDF 06.20.17 Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer Download PDF 06.07.17 Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients’ Clinical Success Correlates with Improved Microbiome Diversity Download PDF 06.01.17 Rebiotix’s Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017 Download PDF 05.04.17 Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017 Download PDF 04.11.17 Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile Download PDF 03.02.17 Rebiotix to Present at Two Investor Conferences Download PDF 02.06.17 Rebiotix to Present at BIO CEO & Investor Conference Download PDF 01.04.17 Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection Download PDF 11.28.16 Rebiotix Appoints Ken F. Blount, Ph.D., Head of External Research Download PDF 11.16.16 Rebiotix to Present at Piper Jaffray 28th Annual Healthcare Conference Download PDF 10.17.16 Data from Rebiotix’s Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016 Download PDF 10.11.16 Rebiotix Receives Patent from the USPTO for Microbiota Restoration Therapy Download PDF 09.06.16 Rebiotix to Present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference Download PDF 01.11.16 Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms Download PDF 12.14.15 Rebiotix and McMaster Children’s Hospital Announce First Patient Treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis Download PDF 12.01.15 Rebiotix Named 2015 Tekne Award Winner Download PDF 11.18.15 Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection Download PDF 10.12.15 Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection Download PDF 12.16.14 Rebiotix Announces First-Ever Randomized Study of a Microbiota-based Drug for Recurrent Clostridium difficile Infection under an FDA IND Download PDF 10.20.14 Rebiotix Presents Additional Results of PUNCH™ CD Study of Microbiota-based Drug Candidate for Recurrent C. difficile Infection at ACG Download PDF 10.09.14 Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective Download PDF 09.17.14 PUNCH™ CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 Download PDF 08.04.14 Rebiotix Inc. Receives $25M for Series B Funding Download PDF 06.03.14 Rebiotix to Present at 2014 BIO International Conference Download PDF 01.13.14 Rebiotix Completes Enrollment in Phase 2 Clinical Trial of New Drug for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea Download PDF 10.31.13 Rebiotix Wins 2013 Leaders in Health Care Award Download PDF 10.15.13 Rebiotix Begins Clinical Trial of Therapy for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea Download PDF 09.05.13 Rebiotix Named Finalist for 2013 Leaders in Health Care Awards Download PDF 07.29.13 Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy Download PDF 06.24.13 FDA Grants Fast Track Designation to Rebiotix for its Microbiota Product for Recurrent Clostridium difficile Infection Download PDF 06.04.13 Rebiotix Inc. Hires Ryan Gordon as Vice President Download PDF 05.01.13 Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors Download PDF